Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion
Cory Kasimov

Cory Kasimov Analyst Performance

Senior Managing Director Equities at Evercore

Cory Kasimov is a stock analyst at Evercore focused in the medical sector, covering 38 publicly traded companies. Over the past year, Cory Kasimov has issued 16 stock ratings, including buy and hold recommendations. While full access to Cory Kasimov's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Cory Kasimov's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
343 Last 11 Years
Buy Recommendations
72.11% 243 Buy Ratings
Companies Covered
38 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy72.1%243 ratings
Hold24.3%82 ratings
Sell3.6%12 ratings

Out of 337 total stock ratings issued by Cory Kasimov at Evercore, the majority (72.1%) have been Buy recommendations, followed by 24.3% Hold and 3.6% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
92.1% of companies on NASDAQ
35 companies
NYSE
7.9% of companies on NYSE
3 companies

Cory Kasimov, an analyst at Evercore, currently covers 38 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
37 companies
97.4%
Finance
1 company
2.6%

Cory Kasimov of Evercore specializes in stock coverage within the Medical sector, with additional focus on Finance companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
31 companies
81.6%
MED - DRUGS
3 companies
7.9%
FIN - INVEST BKRS
1 company
2.6%
BIOTECHNOLOGY
1 company
2.6%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company
2.6%
LARGE CAP PHARMA
1 company
2.6%

About Cory Kasimov

Cory Kasimov Senior Managing Director EquitiesNew York Cory Kasimov is a senior managing director and fundamental research analyst at Evercore ISI, leading coverage of mid- and small-cap biotech companies. Mr. Kasimov’s two decades of research experience includes over 15 years as a senior biotech analyst at J.P. Morgan. His differentiated, actionable research product and educational events have led to consistent recognition in the Institutional Investor (now Extel) All-America Research survey, where he has placed in the top 3 in the large-cap biotech sector and as high as No. 2 in the SMID biotech category. Mr. Kasimov earned an MBA in finance and marketing from Tulane University’s A.B. Freeman School of Business and an MPH in health systems management from Tulane’s School of Public Health and Tropical Medicine. He also holds a B.S. in cellular and molecular biology from Tulane.
Follow on LinkedIn

Cory Kasimov's Ratings History at Evercore

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2/26/2026Reiterated Rating$29.66$45.00Outperform
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2/24/2026Reiterated Rating$7.43$18.00Outperform
Arcellx, Inc. stock logo
ACLX
Arcellx
2/23/2026Set Price Target$113.82$115.00
Arcellx, Inc. stock logo
ACLX
Arcellx
2/23/2026Downgrade$113.71Hold
Moderna, Inc. stock logo
MRNA
Moderna
2/17/2026Set Price Target$43.10$35.00
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
1/22/2026Boost Price Target$756.67$875.00Outperform
Immunome, Inc. stock logo
IMNM
Immunome
12/16/2025Boost Price Target$22.80$40.00Outperform
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
11/26/2025Initiated Coverage$39.86$55.00Outperform
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
11/24/2025Initiated Coverage$22.21$35.00Outperform
Oric Pharmaceuticals, Inc. stock logo
ORIC
Oric Pharmaceuticals
11/20/2025Initiated Coverage$11.48$25.00Outperform
Upstream Bio, Inc. stock logo
UPB
Upstream Bio
11/18/2025Initiated Coverage$25.70$40.00Outperform
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
9/3/2025Initiated Coverage$5.00$12.00Outperform
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
9/3/2025Boost Price Target$49.60$80.00Outperform
Immunome, Inc. stock logo
IMNM
Immunome
8/22/2025Initiated Coverage$10.40$18.00Outperform
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
8/12/2025Boost Price Target$28.25$34.00Outperform
Moderna, Inc. stock logo
MRNA
Moderna
8/1/2025Set Price Target$29.56$32.00
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
5/14/2025Initiated Coverage$29.31$55.00Outperform
Moderna, Inc. stock logo
MRNA
Moderna
5/2/2025Lower Price Target$27.33$32.00In-Line
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4/24/2025Lower Price Target$101.83$185.00Outperform
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
3/12/2025Initiated Coverage$18.50$30.00Outperform
Moderna, Inc. stock logo
MRNA
Moderna
1/27/2025Lower Price Target$43.01$50.00In-Line